The future of heart transplantation

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 2875-2891

  Kobashigawa, J A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Genomics; heart failure; heart transplantation; mechanical circulatory support; regenerative medicine

Indexed keywords

ABATACEPT; ALDOSTERONE ANTAGONIST; ALEMTUZUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; B CELL ACTIVATING FACTOR; BELATACEPT; BORTEZOMIB; CALCINEURIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; EVEROLIMUS; HYDRALAZINE; IVABRADINE; NITRATE; PROTEIN KINASE C INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ASSISTED CIRCULATION; CARDIAC GRAFT REJECTION; CLINICAL EFFECTIVENESS; DISEASE MARKER; GENOMICS; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; NEUROPATHY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TRANSCRIPTOMICS; XENOTRANSPLANTATION;

FEMALE; FORECASTING; GENOMICS; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; MALE; POSTOPERATIVE CARE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY; UNITED STATES;

EID: 84868133553     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04223.x     Document Type: Review

References (215)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al,. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1078-1094.
2. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation;2011: 89-106.
3. Singh TP, Almond CS, Taylor DO, Graham DA,. Decline in heart transplant wait list mortality in the United States following broader regional sharing of donor hearts. Circ Heart Fail 2012; 5: 249-258.
4. Pinderski LJ, Kirklin JK, McGiffin D, et al,. Multi-organ transplantation: Is there a protective effect against acute and chronic rejection? J Heart Lung Transplant 2005; 24: 1828-1833.
5. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49.
6. Yanagida R, Czer LS, Reinsmoen NL, et al,. Impact of virtual cross match on waiting times for heart transplantation. Ann Thorac Surg 2011; 92: 2104-2111.
7. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F,. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.
8. Chin C, Chen G, Sequeria F, et al,. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158-163.
9. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
10. Fontenot JD, Gavin MA, Rudensky AY,. Foxp3 programs the development and function of CD41CD251regulatory T cells. Nat Immunol 2003; 4: 330-336.
11. Wood KJ, Sakaguchi S,. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
12. Kingsley CI, Karim M, Bushell AR, Wood KJ,. CD25+CD4+Regulatory T cells prevent graft rejection: CTLA-4- and IL-10- dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080-1086.
13. Bushell A, Morris P, Wood K,. Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol 1995; 25: 2643-2649.
14. Hamano K, Rawsthorne M, Bushell A, Morris PJ, Wood KJ,. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for the maintenance of tolerance to alloantigen in anti-CD4 treated recipients. Transplantation 1996; 62: 856-860.
15. Tarlinton DM, Batista F, Smith KGC,. The B-cell response to protein antigens in immunity and transplantation. Transplantation 2008; 85: 1698-1704.
16. Carroll MC,. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-986.
17. Newell KA, Asare A, Kirk AD, et al,. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
18. Sagoo P, Perucha E, Sawitzki B, et al,. Development of a crossplatform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
19. Le Texier L, Thebault P, Lavault A, et al,. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11: 429-438.
20. Mauri C, Blair PA,. Regulatory B cells in autoimmunity: Developments and controversies. Nat Rev Rheumatol 2010; 6: 636-643.
21. Carter NA, Vasconcellos R, Rosser EC, et al,. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186: 5569-5579.
22. Blair PA, Norena LY, Flores-Borja F, et al,. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
23. Li XC,. The significance of non-T-cell pathways in graft rejection: Implications for transplant tolerance. Transplantation 2010; 90: 1043-1047.
24. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG,. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation 2008; 86: 889-894.
25. Pallet N, Fougeray S, Beaune P, Legendre C, Thervet E, Anglicheau D,. Endoplasmic reticulum stress: An unrecognized actor in solid organ transplantation. Transplantation 2009; 88: 605-613.
26. Famulski KS, Broderick G, Einecke G, et al,. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483-2495.
27. Jamieson RW, Friend PJ,. Organ reperfusion and preservation. Front Biosci 2008; 13: 221-235.
28. TransMedics. Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation (PROCEEDII). Available at: http://clinicaltrials.gov/ct2/show/NCT00855712. Accessed 2011.
29. Fudaba Y, Spitzer TR, Shaffer J, et al,. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6: 2121-2133.
30. Fehr T, Sykes M,. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008; 21: 1118-1135.
31. Leventhal J, Abecassis M, Miller J, et al,. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124ra28.
32. National Institute of Health. Bone marrow transplant to induce tolerance in heart transplant recipients. Available at: http://clinicaltrials.gov/ct2/ show/NCT00497757. Accessed 2011.
33. Montgomery RA, Locke JE, King KE, et al,. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009; 87: 1246-1255.
34. Roche SL, Burch M, O'Sullivan J, et al,. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant 2008; 8: 208-215.
35. Shin M, Kim SJ,. ABO incompatible kidney transplantation-current status and uncertainties. J Transplant 2011; 2011: 970421.
36. Saczkowski R, Dacey C, Bernier PL,. Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival? Interact Cardiovasc Thorac Surg 2010; 10: 1026-1033.
37. Stussi G, West L, Cooper DK, Seebach JD,. ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation 2006; 13: 390-399.
38. Keogh A, Richardson RM, Rugyrok P, et al,. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
39. Eisen HJ, Tuzcu EM, Dorent R, et al,. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847-858.
40. Mancini D, Pinney S, Burkhoff D, et al,. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
41. Majewski M, Korecka M, Joergensen J, et al,. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from post-transplant lymphoproliferative disorder at allograft protecting doses. Transplantation 2003; 75: 1710-1717.
42. Rubio-Viqueira B, Hidalgo M,. Targeting mTOR for cancer treatment. Adv Exp Med Biol 2006; 587: 309-327.
43. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G,. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
44. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD,. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889.
45. Kushwaha SS, Khalpey Z, Frantz RP, et al,. Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005; 24: 2129-2136.
46. Moloney ED, O'Mahony U, Kirwan M, et al,. Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment. Transplant Proc 2004; 36: 1547-1550.
47. Vo AA, Lukovsky M, Toyoda M, et al,. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
48. Kopchaliiska D, Zachary AA, Montgomery RA, Leffell MS,. Reconstitution of peripheral allospecific CD19 + B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation 2009; 87: 1394-1401.
49. National Institute of Allergy and Infectious Diseases. Prevention of cardiac allograft vasculopathy using rituximab (rituxan) therapy in cardiac transplantation. Available at: http://clinicaltrials.gov/ct2/show/NCT01278745. Accessed 2011.
50. Ciancio G, Burke GW, Warque ME, Miller J,. Efficacy of alemtuzumab in organ transplantation: current clinical status. BioDrugs 2006; 20: 85-92.
51. Teuteberg JJ, Shullo MA, Zomak R, et al,. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010; 10: 382-388.
52. Walsh RC, Everly JJ, Brailey P, et al,. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
53. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J,. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 2011; 30: 1320-1326.
54. Kokko KE, Newell KA, Pearson TC, Pearson TC, Larsen CP,. Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen-4 immunoglobulin. Curr Opin Organ Transplant 2005; 10: 265-2659.
55. Larsen CP, Pearson TC, Adams AB, et al,. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-lg with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
56. Bristol-Myers Squibb. Indication and important safety information, Nulojix (belatacept). Available at: http://www.nulojix.com/hcp/index.aspx. Accessed February 2012.
57. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD,. A new look at T cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-883.
58. Vincenti F, Larsen C, Durrbach A, et al,. Co-stimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
59. Grinyõ J, Charpentier B, Pestana JM, et al,. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521-1527.
60. Hillmen P, Young NS, Schubert J, et al,. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
61. Stegall MD, Diwan T, Raghavaiah S, et al,. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
62. Locke JE, Magro CM, Singer AL, et al,. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
63. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B,. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645.
64. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M,. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010; 89: 903-904.
65. Matz M, Weber U, Mashreghi MF, et al,. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010; 25: 2159-2167.
66. Djamali A, Pietrangeli CE, Gordon RD, Legendre C,. Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. Kidney Int 2010; 78 (Suppl 118): S15-S21.
67. Oropallo MA, Kiefer K, Marshak-Rothstein A, Cancro MP,. Beyond transitional selection: New roles for BLyS in peripheral tolerance. Drug Dev Res 2011; 72: 779-787.
68. Christians U, Strom T, Zhang YL, et al,. Active drug transport of immunosuppressants: New insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28: 39-44.
69. Macphee IA, Fredericks S, Tai T, et al,. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
70. Jacobson PA, Oetting WS, Brearley AM, et al,. Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300-308.
71. Herrero MJ, Almenar L, Jordán C, Sánchez I, Poveda JL, Aliño SF,. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. Transplant Proc 2010; 42: 3181-3182.
72. Ohmann EL, Burckart GJ, Brooks MM, et al,. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 2010; 9: 509-516.
73. Holweg CT, Potena L, Luikart H, et al,. Identification and classification of acute cardiac rejection by intragraft transcriptional profiling. Circulation 2011; 123: 2236-2243.
74. Varagunam M, Yaqoob MM, Dohler B, Opelz G,. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 2009; 360: 874-880.
75. Sarwal MM, Benjamin J, Butte AJ, Davis MM, Wood K, Chapman J,. Transplantomics and biomarkers in organ transplantation: A report from the first international conference. Transplantation 2011; 91: 379-382.
76. Shen-Orr SS, Tibshirani R, Khatri P, et al,. Cell type-specific gene expression differences in complex tissues. Nat Methods 2010; 7: 287-289.
77. Zhang Q, Reed EF,. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010; 22: 682-688.
78. Patel MR, Chang YF, Chen IY, et al,. Longitudinal, noninvasive imaging of T-cell effector function and proliferation in living subjects. Cancer Res 2010; 70: 10141-10149.
79. Brouard S, Mansfield E, Braud C, et al,. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448-15453.
80. Perez-Flores I, Sanchez-Fructuoso A, Santiago JL, et al,. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. Transplant Proc 2009; 41: 2106-2108.
81. Rossano JW, Denfield SW, Kim JJ, et al,. Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. J Heart Lung Transplant 2009; 28: 26-31.
82. Deng MC, Eisen HJ, Mehra MR, et al,. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6: 150-160.
83. Bernstein D, Williams GE, Eisen H, Mital S, Wohlgemuth JG, Klingler TM,. Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. J Heart Lung Transplant 2007; 26: 1270-1280.
84. Pham MX, Teuteberg JJ, Kfoury AG, et al,. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362: 1890-1900.
85. Roedder S, Vitalone M, Khatri P, Sarwal MM,. Biomarkers in solid organ transplantation: Establishing personalized transplantation medicine. Genome Med 2011; 3: 37-48.
86. Hunt SA, Abraham WT, Chin MH, et al,. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
87. Good AH, Cooper DK, Malcolm AJ, et al,. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in man. Transplant Proc 1992; 24: 559-562.
88. Lai L, Kolber-Simonds D, Park KW, et al,. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089-1092.
89. Phelps CJ, Koike C, Vaught TD, et al,. Production of α 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411-414.
90. Cowan PJ, Aminian A, Barlow H, et al,. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69: 2504-2515.
91. Miyagawa S, Yamamoto A, Matsunami K, et al,. Complement regulation in the GalT KO era. Xenotransplantation 2010; 17: 11-25.
92. McGregor CG, Davies WR, Oi K, et al,. Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
93. Knosalla C, Yazawa K, Behdad A, et al,. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9: 1006-1016.
94. Ekser B, Ezzelarab M, Hara H, et al,. Clinical xenotransplantation: The next medical revolution? Lancet 2012; 379: 672-683.
95. Lee KF, Salvaris EJ, Roussel JC, Robson SC, D'Apice AJ, Cowan PJ,. Recombinant pig TFPI effi ciently regulates human tissue factor pathways. Xenotransplantation 2008; 15: 191-197.
96. Roussel JC, Moran CJ, Salvaris EJ, Nandurkar HH, D'Apice AJ, Cowan PJ,. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
97. Crikis S, Lu B, Murray-Segal LM, et al,. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10: 2586-2595.
98. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK,. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN traffi cking into the lungs. FASEB J 2009; 23: 473-482.
99. Xu XC, Goodman J, Sasaki H, Lowell J, Mohanakumar T,. Activation of natural killer cells and macrophages by porcine endothelial cells augments specifi c T-cell xenoresponse. Am J Transplant 2002; 2: 314-322.
100. Saethre M, Schneider M, Lambris J, et al,. Cytokine secretion depends on Galα(1,3)Gal expression in a pig-to-human whole blood model. J Immunol 2008; 180: 6346-6353.
101. The SOLVD Investigators. Effect of enalapril in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
102. Garg R, Yusuf S,. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
103. Flather MD, Yusuf S, Køber L, et al,. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.
104. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
105. Packer M, Coats AJS, Fowler MB, et al,. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
106. Heidenreich PA, Lee TT, Massie BM,. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34.
107. Brophy JM, Joseph L, Rouleau JL,. Beta-blockers in congestive heart failure: A Bayesian meta-analysis. Ann Intern Med 2001; 134: 550-560.
108. Pitt B, Zannad F, Remme WJ, et al,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
109. Pitt B, Remme W, Zannad F, et al,. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
110. Ezekowitz JA, McAlister FA,. Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-477.
111. Taylor AL, Ziesche S, Yancy C, et al,. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-2057.
112. Cleland JG, Daubert JC, Erdmann E, et al,. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
113. Bristow MR, Saxon LA, Boehmer J, et al,. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
114. McAlister FA, Ezekowitz J, Hooton N, et al,. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. JAMA 2007; 297: 2502-2514.
115. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ,. Effects of cardiac resynchronization therapy on overall mortality and mode of death: A meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688.
116. Moss AJ, Zareba W, Hall WJ, et al,. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
117. Bardy GH, Lee KL, Mark DB, et al,. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
118. Desai A, Fang J, Maisel W, Baughman KL,. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials. JAMA 2004; 292: 2874-2879.
119. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA,. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011; 161: 1024-1030. e3.
120. Cohn JN, Ferrari R, Sharpe N,. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582.
121. Mudd JO, Kass DA,. Reversing chronic remodeling in heart failure. Expert Rev Cardiovasc Ther 2007; 5: 585-598.
122. Solomon SD, Skali H, Anavekar NS, et al,. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005; 111: 3411-3419.
123. Udelson JE, Feldman AM, Greenberg B, et al,. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010; 3: 347-353.
124. Abdel-Latif A, Bolli R, Tleyjeh IM, et al,. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 989-997.
125. Birks EJ, Tansley PD, Hardy J, et al,. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355: 1873-1884.
126. Athanasuleas CL, Buckberg GD, Stanley AW, et al,. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 2004; 44: 1439-1445.
127. Koitabashi N, Kass DA,. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol 2011; 9: 147-157.
128. Bansal S, Lindenfeld J, Schrier RW,. Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009; 2: 370-376.
129. Adamopoulos C, Ahmed A, Fay R, et al,. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: Insights from the EPHESUS trial. Eur J Heart Fail 2009; 11: 1099-1105.
130. Albert NM, Yancy CW, Liang L, et al,. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658-1665.
131. Bohm M, Swedberg K, Komajda M, et al,. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
132. Guazzi M, Vicenzi M, Arena R, Guazzi MD,. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1 year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4: 8-17.
133. National Heart, Lung, and Blood Institute (NHLBI). Evaluating the effectiveness of sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure (The RELAX Study). Available at: http://clinicaltrials.gov/ct2/show/NCT00763867. Accessed 2011.
134. Jaski BE, Jessup ML, Mancini DM, et al,. Calcium upregulation by percutaneous administration of gene therapyin cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.
135. Jessup M, Greenberg B, Mancini D, et al,. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
136. Pleger ST, Shan C, Ksienzyk J, et al,. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3: 92ra64.
137. US National Library of Medicine. A study of the safety and efficacy of injectable thymosin beta 4 for treating acute myocardial infarction. Available at: http://clinicaltrials.gov/ct2/show/NCT01311518. Accessed 2011.
138. Anderson ME, Brown JH, Bers DM,. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 2011; 51: 468-473.
139. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D,. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu. Rev. Pharmacol Toxicol 2008; 48: 569-599.
140. Rowell J, Koitabashi N, Kass DA,. TRP-ing up heart and vessels: Canonical transient receptor potential channels and cardiovascular disease. J Cardiovasc Transl Res 2010; 3: 516-524.
141. Creemers EE, Pinto YM,. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011; 89: 265-272.
142. Cleland JG, Calvert MJ, Verboven Y, Freemantle N,. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009; 157: 457-466.
143. Orrego CM, Nasir N, Oliveira GH, et al,. Cellular evidence of reverse cardiac remodeling induced by cardiac resynchronization therapy. Congest Heart Fail 2011; 17: 140-146.
144. Moss AJ, Hall WJ, Cannom DS, et al,. Cardiacresynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361: 1329-1338.
145. Linde C, Abraham WT, Gold MR, et al,. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008, 52: 1834-1843.
146. Cresci S, Kelly RJ, Cappola TP, et al,. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009; 54: 432-444.
147. Rame JE, Tam SW, McNamara D, et al,. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: Results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail 2009; 2: 541-548.
148. Matkovich SJ, Van Booven DJ, Hindes A, et al,. Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest 2010; 120: 280-289.
149. Raynolds MV, Bristow MR, Bush EW, et al,. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-1075.
150. Smith NL, Felix JF, Morrison AC, et al,. The association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: A prospective meta-analysis from the CHARGE consortium. Circ Cardiovasc Genet 2010; 3: 256-266.
151. Morrison AC, Felix JF, Cupples A, et al,. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: The CHARGE consortium. Circ Cardiovasc Genet 2010; 3: 248-255.
152. Nanni L, Romualdi C, Maseri A, Lanfranchi G,. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J Mol Cell Cardiol 2006; 41: 934-948.
153. Matkovich SJ, Zhang, Y, Van Booven DJ, Dorn GW,. Deep mRNA sequencing for invivo functional analysis of cardiac transcriptional regulators: Application to Galphaq. Circulation Res 2010; 106: 145901467.
154. Creemers EE, Sutherland LB, Oh J, Barbosa AC, Olson EN,. Coactivation of MEF2 by the SAP domain proteins myocardin and MASTR. Mol Cell 2006; 23: 83-96.
155. Dorn GW 2nd,. Therapeutic potential of microRNAs in heart failure. Curr Cardiol Rep 2010; 12: 209-215.
156. van Rooij E, Quiat D, Johnson BA, et al,. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009; 17: 662-673.
157. Terracciano CM, Hardy J, Birks EJ, Khaghani A, Banner NR, Yacoub MH,. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 2004; 109: 2263-2265.
158. Kawase Y, Ly HQ, Prunier F, et al,. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
159. Miller LW, Pagani FD, Russell SD, et al,. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-896.
160. Slaughter MS, Rogers JG, Milano CA, et al,. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
161. Slaughter MS, Pagani FD, Rogers JG, et al,. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29 (4 Suppl): S1-S39.
162. Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW,. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant 2009; 28: 231-236.
163. Lietz K, Long JW, Kfoury AG, et al,. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation 2007; 116: 497-505.
164. Teuteberg J, Ewald G, Adamson R, et al,. Risk assessment for continuous flow left ventricular assist devices: Does the destination therapy risk score work? J Am Coll Cardiol 2012; 60: 44-51.
165. Matthews JC, Koelling TM, Pagani FD, Aaronson KD,. The right ventricular failure risk score. J Am Coll Cardiol 2008; 51: 2163-2172.
166. Fitzpatrick JR, Frederick JR, Hsu VM, et al,. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008; 27: 1286-1292.
167. Stevenson LW, Pagani FD, Young JB, et al,. INTERMACS profiles of advanced heart failure: The current picture. J Heart Lung Transplant 2009; 28: 535-541.
168. Dardas T, Mokadam N, Pagani F, Aaronson K, Levy WC,. Transplant
169. John R, Long JW, Massey HT, et al,. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 2011; 141: 932-939.
170. Kiernan MS, Krishnamurthy B, Kapur NK,. Percutaneous right ventricular assist via the internal jugular vein in cardiogenic shock complicating an acute inferior myocardial infarction. J Invasive Cardiol 2010; 22: E23-E26.
171. Granfeldt H, Hellgren L, Dellgren G, et al,. Experience with the Impella recovery axial-flow system for acute heart failure at three cardiothoracic centers in Sweden. Scand Cardiovasc J 2009; 43: 233-239.
172. Klotz S, Meyns B, Simon A, et al,. Partial mechanical long-term support with the CircuLite Synergy pump as bridge-to-transplant in congestive heart failure. Thorac Cardiovasc Surg 2010; 58 (Suppl 2): S173-S178.
173. Seyfarth M, Sibbing D, Bauer I, et al,. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52: 1584-1588.
174. Cheng JM, den Uil CA, Hoeks SE, et al,. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: A meta-analysis of controlled trials. Eur Heart J 2009; 30: 2102-2108.
175. Wieselthaler GM, O Driscoll G, Jansz P, Khaghani A, Strueber M,; HVAD Clinical Investigators. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant 2010; 29: 1218-1225.
176. Waters B, Sample A, Smith J, Bonde P,. Toward total implantability using free-range resonant electrical energy delivery system: Achieving untethered ventricular assist device operation over large distances. Cardiol Clin 2011; 29: 609-625.
177. Hall JL, Birks EJ, Grindle S, et al,. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J 2007; 28: 613-627.
178. Hall JL, Fermin DR, Birks EJ, et al,. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol 2011; 57: 641-652.
179. Matkovich SJ, Van Booven DJ, Youker KA, et al,. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009, 119: 1263-1271.
180. Birks EJ, George RS, Hedger M, et al,. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacologic therapy: A prospective study. Circulation 2011; 123: 381-390.
181. Butler CR, Jugdutt BI,. The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: Implications for heart failure in the elderly. Heart Fail Rev 2012; 17: 615-633.
182. Anastasiadis K, Antonitsis P, Argiriadou H, et al,. Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J Transl Med 2011; 9: 12.
183. Copeland JG, Smith RG, Arabia FA, et al,. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351: 859-867.
184. Copeland JG, Copeland H, Gustafson M, et al,. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 2012; 143: 727-734.
185. SynCardia Systems. Inc. SynCardia Freedom Driver System Study. Available at: http://clinicaltrials.gov/ct2/show/NCT00733447. Accessed 2010.
186. Ando Y, Kitao T, Nagaoka E, et al,. One-month biocompatibility evaluation of the pediatric TinyPump in goats. Artif Organs 2011; 35: 813-818.
187. Oh H, Bradfute SB, Gallardo TD, et al,. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003; 100: 12313-12318.
188. Beltrami AP, Barlucchi L, Torella D, et al,. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003; 114: 763-776.
189. Schächinger V, Assmus B, Britten MB, et al,. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: Final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690-1699.
190. Bolli R, Chugh AR, D'Amario D, et al,. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomized phase 1 trial. Lancet 2011; 378: 1847-1857.
191. Lipinski MJ, Biondi-Zoccai GG, Abbate A, et al,. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007, 50: 1761-1767.
192. Orlic D, Kajstura J, Chimenti S, et al,. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
193. Chen SL, Fang WW, Ye F, et al,. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95.
194. Schächinger V, Assmus B, Erbs S, et al,. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: Insights from the Reinfusion of Enriched Progenitor cells And Infarct Remodelling in Acute Myocardial Infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009; 11: 973-979.
195. Meyer GP, Wollert KC, Lotz J, et al,. Intracoronary bone marrow cell transfer after myocardial infarction: Eighteen months' follow-up data from the randomized, controlled BOOST (Bone marrOw transfer to enhance ST-elevation infarct regeneration) Trial. Circulation 2006; 113: 1287-1294.
196. Mirotsou M, Zhang Z, Deb A, et al,. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad. Sci USA 2007; 104: 1643-1648.
197. Menasche P, Alfieri O, Janssens S, et al,. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-1200.
198. Hosoda T,. C-kit-positive cardiac stem cells and myocardial regeneration. Am J Cardiovasc Dis 2012; 2: 58-67.
199. van Laake LW, Passier R, Doevendans PA, Mummery CL,. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res 2008; 102: 1008-1010.
200. Martinez-Fernandez A, Nelson TJ, Yamada S, et al,. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res 2009; 105: 648-656.
201. Zhang J, Wilson GF, Soerens AG, et al,. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009; 104: e30-e41.
202. Bergmann O, Bhardwaj RD, Bernard S, et al,. Evidence for cardiomyocyte renewal in humans. Science 2009; 324: 98-102.
203. Smith RR, Barile L, Cho HC, et al,. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007; 115: 896-908.
204. Johnston PV, Sasano T, Mills K, et al,. Engraftment, differentiation, and functional benefits of autologous cardiospherederived cells in porcine ischemic cardiomyopathy. Circulation 2009; 120: 1075-1083.
205. Chimenti I, Smith RR, Li T-S, et al,. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010; 106: 971-980.
206. Yoon C-H, Koyanagi M, Iekushi K, et al,. Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: Role of cardiovascular lineage commitment. Circulation 2010; 121: 2001-2011.
207. Urbich C, Aicher A, Heeschen C, et al,. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-742.
208. Makkar RR, Smith RR, Cheng K, et al,. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
209. Furuta A, Miyoshi S, Itabashi Y, et al,. Pulsatile cardiac tissue grafts using a novel three-dimensional cell sheet manipulation technique functionally integrates with the host heart, in vivo. Circ Res 2006; 98: 705-712.
210. Miyagawa S, Sawa Y, Sakakida S, et al,. Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: Their integration with recipient myocardium. Transplantation 2005; 80: 1586-1595.
211. Sawa Y,. Myocardial regeneration for heart failure. Nippon Rinsho 2010; 68: 719-725.
212. Stevens KR, Kreutziger KL, Dupras SK, et al,. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 2009; 106: 16568-16573.
213. Lesman A, Habib M, Caspi O, et al,. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng Part A 2010; 16: 115-125.
214. Ott HC, Matthiesen TS, Goh SK, et al,. Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14: 213-221.
215. Taylor DA,. From stem cells and cadaveric matrix to engineered organs. Curr Opin Biotechnol 2009; 20: 598-605.